United Capital Financial Advisers LLC Raises Position in Illumina, Inc. (ILMN)

United Capital Financial Advisers LLC raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,744 shares of the life sciences company’s stock after buying an additional 1,829 shares during the period. United Capital Financial Advisers LLC’s holdings in Illumina were worth $5,417,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ILMN. Advocacy Wealth Management Services LLC acquired a new position in shares of Illumina during the first quarter valued at about $102,000. Gemmer Asset Management LLC raised its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Illumina during the first quarter valued at about $117,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock valued at $204,000 after buying an additional 42 shares during the last quarter. Finally, Probity Advisors Inc. acquired a new position in shares of Illumina during the first quarter valued at about $204,000. 96.85% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Illumina, Inc. (ILMN) traded up 0.01% on Tuesday, reaching $176.61. 518,715 shares of the company were exchanged. The stock has a market capitalization of $25.79 billion, a price-to-earnings ratio of 35.74 and a beta of 0.76. The stock has a 50-day moving average price of $178.79 and a 200 day moving average price of $163.12. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. During the same period last year, the firm posted $0.71 EPS. The company’s revenue was up 4.5% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post $3.63 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/06/20/united-capital-financial-advisers-llc-raises-position-in-illumina-inc-ilmn.html.

Several brokerages recently issued reports on ILMN. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price objective on the stock in a report on Monday, April 24th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. Evercore ISI raised shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective on the stock in a report on Monday, February 27th. Leerink Swann raised shares of Illumina from a “market perform” rating to an “outperform” rating and set a $195.00 price objective on the stock in a report on Monday, March 20th. Finally, Deutsche Bank AG reissued a “hold” rating and set a $175.00 price objective (up from $165.00) on shares of Illumina in a report on Saturday, April 29th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $165.02.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the firm’s stock in a transaction on Friday, April 7th. The shares were sold at an average price of $172.79, for a total transaction of $103,674.00. Following the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $2,948,661.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Omead Ostadan sold 1,672 shares of the firm’s stock in a transaction on Friday, March 24th. The stock was sold at an average price of $170.00, for a total transaction of $284,240.00. Following the transaction, the executive vice president now directly owns 29,586 shares in the company, valued at $5,029,620. The disclosure for this sale can be found here. Insiders have sold a total of 76,457 shares of company stock worth $13,761,498 over the last three months. 1.60% of the stock is currently owned by insiders.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply